Mon, March 21, 2011
[ Mon, Mar 21st 2011 ]: Market Wire
30 p.m. ET
Sun, March 20, 2011
Fri, March 18, 2011
Thu, March 17, 2011
Wed, March 16, 2011
Tue, March 15, 2011
Mon, March 14, 2011
[ Mon, Mar 14th 2011 ]: Market Wire
30 AM E.T.
Sun, March 13, 2011
Sat, March 12, 2011
Fri, March 11, 2011
[ Fri, Mar 11th 2011 ]: Market Wire
Covidien????????????????FDA??
Thu, March 10, 2011
Wed, March 9, 2011
Tue, March 8, 2011
Mon, March 7, 2011
Sat, March 5, 2011
Fri, March 4, 2011
Thu, March 3, 2011
Wed, March 2, 2011
Tue, March 1, 2011

BioSante Pharmaceuticals, Inc. to Present at Roth Annual Growth Stock Conference

  Copy link into your clipboard //health-fitness.news-articles.net/content/2011/ .. sent-at-roth-annual-growth-stock-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

LINCOLNSHIRE, Ill.--([ BUSINESS WIRE ])--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will be presenting at the Roth 23rd Annual Growth Stock Conference. The conference will take place March 13-16, 2011 in Dana Point, CA.

Stephen M. Simes, BioSantea™s president & CEO, will speak Tuesday, March 15, 2011 at 10:30 am PT. He will provide an overview of the company, as well as an update on the LibiGel® (testosterone gel) Phase III clinical development program. A live audio webcast of Mr. Simesa™ remarks may be accessed at: [ http://www.wsw.com/webcast/roth24/bpax/ ]. The webcast will be archived approximately three hours after the live event and will be available for 90 days.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSantea™s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gela", a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: [ www.biosantepharma.com ].